About Rebiotix
Rebiotix is a Healthcare company based in Roseville (United States) founded in 2011, and was acquired by Ferring Pharmaceuticals in April 2018. Microbiota restoration therapies are developed for gastrointestinal infections. Rebiotix has raised $29.3 million across 3 funding rounds from investors including Ferring Pharmaceuticals. Rebiotix offers products and services including Donor Program. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Diversified. Its legal entity is Rebiotix Inc. Its competitors include Vir Biotechnology, Vaxcyte and Cidara Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Rebiotix was founded in 2011 and is headquartered in Roseville, United States. Biologic drugs are developed by the company for gastrointestinal diseases, with a focus on recurrent Clostridium difficile infections through microbiome-based approaches. RBX2660, a microbiota suspension derived from fecal transplants, is advanced as a primary therapy. Additional efforts target ulcerative colitis and metabolic syndrome within the biotechnology sector.
- Headquarters Roseville, United States
- Stage Acquired
- SectorsHealthcare
- Website rebiotix.com
- Social LinkedIn X Facebook
- Acquired by Ferring Pharmaceuticals (Apr 2018)
- Legal Name Rebiotix Inc
- Total Equity Funding$29.3M (USD)
in 3 rounds
- Latest Funding Round$8.52M (USD), Series B
Sep 2017
- Investors
- Acquired byFerring Pharmaceuticals
(Apr 2018)
Products & Services of Rebiotix
Rebiotix offers a comprehensive portfolio of products and services, including Donor Program.
Program for donor-related activities in pharmaceuticals context.
Funding Insights of Rebiotix
Rebiotix has successfully raised a total of $29.3M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $8.52 million completed in September 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $29.3M
- Total Rounds 3
- Last Round Series B — $8.52M
- First Round $2.78M
(Nov 2011)
All 3 funding rounds of Rebiotix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2017 | $8.52M | Series B | – | – | – |
| Jul 2014 | $18M | Series B | – | – | – |
| Nov 2011 | $2.78M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in Rebiotix
Rebiotix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ferring Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Provider of drugs in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics | 1950 | ferring.com | Saint Prex, Switzerland |
Investor details for Rebiotix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rebiotix
19 people are tracked at Rebiotix (6 in leadership, 13 in team).
| Name | Role | Group |
|---|---|---|
Lee Jones | Founder, President & CEO | Leadership |
Sara Wall | Senior Director, Technical Operations | Leadership |
Greg Fluet | COO & Site Head | Leadership |
Ken F. Blount | Chief Scientific Officer & VP of Microbiome Research | Leadership |
Tom Willard | VP of Upstream Marketing & Market Strategy | Leadership |
Clark Haake | Director Of Finance And Controller | Leadership |
Karen Gott | Validation Engineer | Team |
Elad Fadlon | Information Technology System Analyst | Team |
Carol Bchara | Marketing Specialist | Team |
Tanvi Sankar | Marketing Specialist | Team |
Travis Yano | Digital Analytics & Marketing Contractor | Team |
Ryan Campbell | Finance Consultant | Team |
Mark Reich | Engineering/Validation Manager | Team |
Kristi Strandberg | Senior Scientist II, Microbiology | Team |
Beth Adamowicz | Research Scientist, Microbiome Bioinformatics | Team |
Jennifer Wagner | Senior Human Resources Manager | Team |
Brad Staskiewicz | Research Development Process Engineer | Team |
Britney Mullenbach | Associate Validation Engineer | Team |
Stefano Rosati | Bioinformatics Manager | Team |
Complete people profiles for Rebiotix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Rebiotix
4 dated milestones of Rebiotix across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Rebiotix is founded.
- Funding First funding round of $2.8M.
- Funding Latest funding round, Series B, of $8.5M.
- Exit Acquired by Ferring Pharmaceuticals.
Competitors of Rebiotix
Rebiotix has 3 listed competitors in our database, 3 of them funded. They include Vir Biotechnology, Vaxcyte and Cidara Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases | |
| vaxcyte.com | 2013 | Foster, United States | $347M | 254 | Vaccines for infectious diseases are developed using cell-free protein synthesis. | |
| cidara.com | 2013 | San Diego, United States | $78.35M | 90 | Novel anti-infectives for bacterial and fungal infections are developed. |
Detailed competitors of Rebiotix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Rebiotix
Websites that share an audience with Rebiotix (rebiotix.com).
Websites whose visitors overlap most with Rebiotix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| fiercebiotech.com | 100% | 858.3K | #81,022 | View details | |
fhs.mcmaster.ca | fhs.mcmaster.ca | 86% | – |
Top companies in Microbiome Therapeutics
3 companies that operate in the same segment as Rebiotix (Microbiome Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | 55 | ||
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | 12 | ||
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rebiotix
Complete news archive for Rebiotix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rebiotix
Rebiotix was founded in 2011.
Rebiotix is headquartered in Roseville, United States. It is registered at Roseville, California, United States.
Rebiotix is a funded company, having raised a total of $29.3M across 3 funding rounds to date. The company's 1st funding round was a Seed of $2.78M, raised on Nov 2011.
Rebiotix was founded in 2011 and is headquartered in Roseville, United States. Biologic drugs are developed by the company for gastrointestinal diseases, with a focus on recurrent Clostridium difficile infections through microbiome-based approaches. RBX2660, a microbiota suspension derived from fecal transplants, is advanced as a primary therapy. Additional efforts target ulcerative colitis and metabolic syndrome within the biotechnology sector.
Rebiotix's top competitors include Vaxcyte, Vir Biotechnology and Cidara Therapeutics.
Rebiotix offers Donor Program.
Rebiotix has 1 investor. Key investors include Ferring Pharmaceuticals.
Rebiotix operates through Rebiotix Inc.
Yes. Rebiotix was acquired by Ferring Pharmaceuticals in April 2018.